文献速递乳腺MR

基于MRI预测乳腺癌患者Ki-67水平的影像组学研究:质量与临床转化

The quality and clinical translation of radiomics studies based on MRI for predicting Ki-67 levels in patients with breast cancer.
PubMed 文献 · Br J Radiol · 2023-09-19

本综述检索PubMed、Embase和Web of Science,纳入18项基于MRI预测乳腺癌Ki-67水平的影像组学研究,用影像组学质量评分(RQS)评估方法学质量,平均RQS为10.17(标准差3.54)。Meta分析显示,在影像组学预测Ki-67水平方面,表观扩散系数(ADC)的汇总曲线下面积(AUC)为0.969,表现优于动态对比增强(DCE)MRI。

要点

  • 基于MRI预测乳腺癌Ki-67的影像组学研究平均RQS仅10.17,方法学质量不令人满意。
  • ADC影像组学预测Ki-67的汇总AUC为0.969,优于DCE MRI。
  • 纳入研究均未涉及体模研究、cut-off分析、前瞻性研究、成本效益分析或开放科学与数据。

核心结论

  • Ki-67指数是具有高临床价值的常见肿瘤生物标志物,影像组学是一种不断发展的定量数据挖掘方法,有助于从医学图像预测肿瘤生物标志物;但所评价研究的RQS质量不令人满意,有充足改进空间。

研究设计与样本

  • 本综述检索PubMed、Embase和Web of Science中关于乳腺癌患者影像组学的研究,纳入18项研究,采用影像组学质量评分(RQS)评估方法学质量,并使用RevMan 5.4、Meta-DiSc v.1.4和IBM SPSS v.26.0进行统计分析。

诊断标准与关键数值

  • 纳入18项基于MRI预测乳腺癌Ki-67水平的影像组学研究,平均RQS为10.17(标准差3.54)。
  • Meta分析显示,影像组学预测Ki-67水平时,ADC的汇总AUC为0.969,表现优于DCE MRI。
  • 所有纳入研究均未包含以下条目:对所有扫描仪进行体模研究、cut-off分析、前瞻性研究、成本效益分析、开放科学与数据。

临床应用与阅片要点

  • 作者认为,未来研究者应更多关注开放科学与数据、外部验证、体模研究、公开的影像组学数据库以及影像组学实践的标准化。

局限性

  • 所评价研究的RQS质量不令人满意,有充足改进空间。
  • 纳入研究均未涉及对所有扫描仪进行体模研究、cut-off分析、前瞻性研究、成本效益分析或开放科学与数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To evaluate the methodological quality of radiomics literature predicting Ki-67 levels based on MRI in patients with breast cancer (BC) and to propose suggestions for clinical translation.

METHODS: In this review, we searched PubMed, Embase, and Web of Science for studies published on radiomics in patients with BC. We evaluated the methodological quality of the studies using the Radiomics Quality Score (RQS). The Cochrane Collaboration's software (RevMan 5.4), Meta-DiSc (v. 1.4) and IBM SPSS (v. 26.0) were used for all statistical analyses.

RESULTS: Eighteen studies met our inclusion criteria, and the average RQS was 10.17 (standard deviation [SD]: 3.54). None of these studies incorporated any of the following items: a phantom study on all scanners, cut-off analyses, prospective study, cost-effectiveness analysis, or open science and data. In the meta-analysis, it showed apparent diffusion coefficient (ADC) played a better role to predict Ki-67 level than dynamic contrast-enhanced (DCE) MRI in the radiomics, with the pooled area under the curve (AUC) of 0.969.

CONCLUSION: Ki-67 index is a common tumor biomarker with high clinical value. Radiomics is an ever-growing quantitative data-mining method helping predict tumor biomarkers from medical images. However, the quality of the reviewed studies evaluated by the RQS was not so satisfactory and there are ample opportunities for improvement. Open science and data, external validation, phantom study, publicly open radiomics database and standardization in the radiomics practice are what researchers should pay more attention to in the future.

ADVANCES IN KNOWLEDGE: The RQS tool considered the radiomics used to predict the Ki-67 level was of poor quality. ADC performed better than DCE in radiomic prediction. We propose some measures to facilitate the clinical translation of radiomics.

来源:Br J Radiol,查看原文。版权归原作者所有。

引用

  1. Wang M, Mei T, Gong Y, et al. The quality and clinical translation of radiomics studies based on MRI for predicting Ki-67 levels in patients with breast cancer. Br J Radiol. 2023. PMID: 37724784. doi:10.1259/bjr.20230172

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。